

QIBA Q-CT Committee Weekly Update

Monday, October 04, 2010

11 AM CDT

Call Summary

In attendance:

Andrew Buckler, MS (Co-chair)
P. David Mozley, MD (Co-chair)
Lawrence Schwartz, MD (Co-chair)
Maria Athelougou, MD
Hubert Beaumont
David A. Clunie, MBBS
Patricia E. Cole, PhD, MD
Jon T. DeVries
Charles Fenimore, PhD
Kavita Garg, MD
David Gustafson, PhD
Michael McNitt-Gray, PhD
James Mulshine, MD

Ganesh Saiprasad, PhD
Robert Schwanke
Daniel C. Sullivan, MD
Ying Tang, PhD
Binsheng Zhao, DSc

RSNA

Fiona Miller
Joe Koudelik
Madeleine McCoy
Julie Lisiecki

Corporate Visits Overview (Mr Buckler)

- Corporate visits designed to present the QIBA model as we have developed it with a view to clearly articulating the vendor's interest in participating
- Various slides designed specifically for interactive discussions with company representatives
- Slides set the stage for the CT modality, describe the QIBA mission ("why QIBA"), specify current disease activities (e.g., lung cancer, emphysema), acknowledgments, and areas needing specific attention and feedback
- Pivotal message is to describe where QIBA came from, and why QIBA is suited to help
- Proposal to send out the slide deck in advance of meetings to acquaint vendors with the broader scope and mission of QIBA and quantitative imaging.
- Wide-ranging (general) audience expected; reminder to keep message simple and targeted to avoid information overload
- Fundamental issues are measurement problems; need to mention the measurement issues associated with CT encountered in the field and support with clear examples, e.g., illustrate the variability seen in phantoms (1A) and issues associated in 1B
- Illustrate problem, then illustrate QIBA's approach to solution
- Anyone interested to email Mr Buckler for slide set
- Vendor engagement is critical
- Need to show what products vendors could pursue; products not at market due to issues QIBA is working on now
- Must tie QIBA efforts to vendor interest, i.e., product development
- Common terminology needs to be chosen carefully for this meeting; the QIBA message needs to make sense to all
- Drs McNitt-Gary and Mulshine to assist with developing and fine-tuning slide content
- Need to get message across to vendors and clinicians while not worsening radiation dose

FDA Briefing Document (Ying Tang, PhD)

- Discussion regarding approach to scope beyond lung cancer
- Categories proposed based on organ system
- Six liver-based papers reviewed
- Liver needs more support to be added to the vCT Briefing Document
- Meta-analysis also needed to identify variables to look into
 - May prove difficult due to non-uniformity of public databases
 - Feedback needed
- QIBA could help unify standards on investigator collections; development of guidelines proposed
- One activity is to develop performance characterization and statistical evaluations of biomarkers; need biostatistician expert engagement
- Must set proper scope to provide meaningful results
- MICCAI Liver Challenge (2007-2008) may have some good experience with liver studies; many vendors participated on this challenge

Next Steps:

- Drs McNitt-Gary and Mulshine to assist with developing and fine-tuning corporate visit slide content
 - Mr Buckler requests feedback
 - Anyone interested to email Mr Buckler for slide set
- Next call: October 18th, 2010 at 11 am CDT